Last updated: April 1, 2026
Quick Answer: After completing melanoma treatment in Ontario, survivors enter a structured follow-up program involving regular skin exams, imaging, and blood work — the schedule and intensity depend on the stage originally diagnosed. Most follow-up care is covered by OHIP and coordinated through a dermatologist, surgical oncologist, or medical oncologist. Staying consistent with these appointments is the single most important thing a melanoma survivor can do.
For a melanoma survivor, what follow-up care looks like in Ontario is a structured, stage-specific program designed to catch recurrence early, monitor for new skin cancers, and support overall health after treatment. It is not a single appointment — it is an ongoing relationship with a care team.
Ontario's cancer care system, coordinated largely through Cancer Care Ontario (now part of Ontario Health), provides clinical practice guidelines that oncologists, dermatologists, and surgeons follow. The specific providers involved depend on the stage of melanoma and the type of treatment received.
The core goals of follow-up care are:
The schedule varies by stage at diagnosis, but Ontario follows evidence-based intervals that balance early detection against the practical demands on the health system.
Stage I survivors (thin melanomas, no lymph node involvement) typically have a lower recurrence risk. Most Ontario oncologists recommend:
Stage II melanomas carry a moderate recurrence risk. Typical Ontario follow-up:
Higher-stage survivors require closer monitoring:
💡 Important: These are general frameworks. Individual schedules are set by the treating oncologist based on specific pathology, surgical margins, treatment history, and patient risk factors.
Each appointment for a melanoma survivor in Ontario typically includes a combination of physical examination, imaging (at higher stages), and conversation about symptoms and wellbeing.
For survivors who had a sentinel lymph node biopsy, the nodes in that region are checked carefully at every visit.
TestPurposeTypical FrequencyCT scan (chest/abdomen/pelvis)Detect distant metastasesEvery 6–12 months (Stage III–IV)PET scanFull-body metabolic activityAs clinically indicatedBrain MRIRule out brain metastasesStage III–IV, as indicatedUltrasound (regional nodes)Monitor lymph node basinsStage II–III, every 6 monthsLDH blood testMarker of tumor burdenAt each visit for Stage III–IV
Stage I survivors generally do not require routine imaging unless symptoms suggest a problem.
Providers ask specifically about:
These questions matter because early-stage recurrence symptoms are often subtle.
A melanoma survivor in Ontario may see several different providers depending on their stage and treatment history. Understanding who does what prevents confusion and gaps in care.
Common providers involved:
Melanoma survivors need to know what to look for between appointments. Recurrence can be local (at or near the original site), regional (in nearby lymph nodes), or distant (in organs like the lungs, liver, or brain).
Warning signs to report immediately:
For survivors who had melanoma on the foot or lower extremity, it's worth knowing that early melanoma on the bottom of the foot can be easy to miss during self-exams. Checking between toes and on the soles is important.
🔍 Self-exam tip: Perform a full-body skin check once a month in good lighting. Use a hand mirror for hard-to-see areas like the back, scalp, and behind the ears. A partner can help with areas that are difficult to examine alone.
For most melanoma survivors in Ontario, follow-up care through the public system is covered by OHIP. This includes specialist visits, imaging ordered by a physician, blood work, and biopsies when medically indicated.
What OHIP typically covers:
What may not be covered:
Wait times for dermatology in Ontario can be significant. Some survivors choose to supplement their OHIP care with visits to a private dermatologist in Ontario for faster access to full-body skin checks and mole monitoring between oncology appointments.
Lifestyle plays a real role in long-term outcomes for melanoma survivors. While no lifestyle change eliminates recurrence risk, several evidence-based habits reduce the risk of new skin cancers and support overall health.
Sun avoidance raises the question of vitamin D deficiency. Survivors should have their vitamin D levels checked regularly and supplement as directed by their physician. Do not self-prescribe high-dose supplements without guidance.
Emerging research (as of 2026) suggests that regular physical activity and maintaining a healthy weight may support immune function in cancer survivors. The Canadian Cancer Society recommends at least 150 minutes of moderate activity per week for cancer survivors, though individual capacity varies.
For a broader look at evidence-based skin health practices, the building a skin-healthy lifestyle guide offers practical, research-backed recommendations.
The psychological burden of melanoma survivorship is real and often underestimated. Anxiety about recurrence, changes in body image after surgery, and the stress of ongoing surveillance are all common.
Available resources in Ontario:
"Survivorship doesn't end when treatment ends. The follow-up period is its own chapter, and having support through it makes a measurable difference in quality of life."
Even well-informed survivors sometimes fall into patterns that reduce the effectiveness of follow-up care.
Mistakes to avoid:
Q: How long does follow-up care last after melanoma treatment?
Most oncologists recommend lifelong annual skin surveillance after melanoma, even for Stage I survivors. The intensive phase (every 3–6 months) typically covers the first 2–5 years, when recurrence risk is highest.
Q: Can my family doctor manage my melanoma follow-up?
For low-risk Stage I survivors after discharge from oncology, a trained family physician can perform annual skin checks. However, any concerning lesion should prompt a referral back to a dermatologist or surgical oncologist.
Q: Will I need imaging after Stage I melanoma?
Generally, no. Routine imaging is not recommended for Stage I melanoma survivors in the absence of symptoms. Imaging is reserved for higher-stage disease or when clinical findings suggest recurrence.
Q: What is the risk of getting a second melanoma?
Melanoma survivors have a significantly higher lifetime risk of developing a second primary melanoma compared to the general population. This is one of the primary reasons lifelong dermatologic surveillance is recommended.
Q: Is mole mapping covered by OHIP?
Standard dermoscopy performed during a dermatologist visit is OHIP-covered. Comprehensive digital mole mapping (full-body photography with digital dermoscopy) offered at private clinics is typically not covered and costs vary. See mole mapping clinics in Toronto for options and pricing.
Q: What should I do if I notice a suspicious spot between appointments?
Contact your dermatologist or oncologist promptly — don't wait for your next scheduled visit. Most Ontario cancer centres have mechanisms for urgent triage of new concerns in active patients.
Q: Are there specific melanoma types that need different follow-up?
Yes. Acral melanoma (occurring on palms, soles, and under nails) and amelanotic melanoma (which lacks pigment) can be harder to detect during self-exams and may require more careful clinical surveillance.
Q: Can I travel during the follow-up period?
Yes, with planning. Ensure you have travel insurance that covers cancer-related complications. Inform your oncologist of extended travel plans so follow-up appointments can be scheduled around them.
Q: What happens if recurrence is detected?
Recurrence triggers a new staging workup and a multidisciplinary team review. Treatment options depend on the location and extent of recurrence and may include surgery, immunotherapy, targeted therapy, or radiation. For an overview of what advanced disease involves, see advanced melanoma stages.
Q: Is immunotherapy follow-up different from surgery-only follow-up?
Yes. Survivors who received immunotherapy (such as checkpoint inhibitors like pembrolizumab or nivolumab) require monitoring for immune-related adverse effects, which can emerge months or even years after treatment ends. This includes thyroid function tests, glucose monitoring, and assessment for autoimmune symptoms.
Being a melanoma survivor in Ontario means entering a well-supported, evidence-based system of follow-up care — but it also requires active participation. The follow-up schedule is not just a formality. It is the safety net that catches problems early, when they are most treatable.
Actionable next steps:
For those looking for specialized melanoma care in Ontario, connecting with a melanoma oncologist near you in Toronto is a strong starting point.
